Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies
详细信息 查看全文
- 作者：Jeffrey S. Ross ; Laurie M. Gay ; Kai Wang ; Siraj M. Ali ; Saranya Chumsri ; Julia A. Elvin ; Ron Bose ; Jo-Anne Vergilio ; James Suh ; Roman Yelensky ; Doron Lipson ; Juliann Chmielecki ; Stanley Waintraub ; Brian Leyland-Jones ; Vincent A. Miller and Philip J. Stephens
- 刊名：Cancer
- 出版年：2016
- 出版时间：September 1, 2016
- 年：2016
- 卷：122
- 期：17
- 页码：2654-2662
- 全文大小：231K
- ISSN：1097-0142
文摘
Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)-targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti-HER2 therapeutics were identified.